Urokinase treatment for severe neurological complications in a patient with thrombotic thrombocytopenic purpura.
In a patient with thrombotic thrombocytopenic purpura (TTP) severe neurological complications leading to coma were repeatedly reversed by treatment with urokinase. Although the therapeutic modalities for TTP still appear to be a matter of debate, thrombolytic treatment could be considered in TTP patients with severe organ involvement before the corresponding function is completely compromised.
D000305:Adrenal Cortex Hormones / Q000494:pharmacology; D000328:Adult; D001157:Arterial Occlusive Diseases / Q000150:complications; D001792:Blood Platelets / Q000187:drug effects; D010450:Endopeptidases / Q000627:therapeutic use*; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009422:Nervous System Diseases / Q000150:complications / Q000188:drug therapy*; D010949:Plasma / Q000637:transplantation; D010951:Plasma Exchange; D011697:Purpura, Thrombotic Thrombocytopenic / Q000150:complications*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D006493:Heparin; D010450:Endopeptidases; D014568:Urokinase-Type Plasminogen Activator